Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Soleno Therapeutics (SLNO) Other Operating Expenses (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Other Operating Expenses for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $1.7 million; the TTM value through Dec 2025 reached $8.2 million, changed N/A, while the annual FY2025 figure was $8.2 million, 154.04% up from the prior year.
  • Other Operating Expenses hit $1.7 million in Q4 2025 for Soleno Therapeutics, down from $1.8 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.0 million in Q1 2025 and bottomed at $1.7 million in Q4 2025.